Complications of the gestational period in patients with type 1 multiple endocrine neoplasia syndrome

Cover Page

Cite item

Full Text

Abstract

Type 1 endocrine neoplasia syndrome is a genetically determined autosomal dominant disease and is manifested by the development of malignant transformation and/or hyperplasia of two or more endocrine glands. Women’s reproductive health problems are mainly caused by damage to the parathyroid glands, pituitary gland, thyroid gland and adrenal glands. Hyperparathyroidism is observed in 90-100% of patients and leads to the development of nephrocalcinosis, pyelonephritis, acute renal failure, pathological bone fractures, cardiovascular failure, increased blood pressure, preeclampsia, which are accompanied by fetal hypoxia, intrauterine growth retardation, and a lethal outcome is possible, such as death for the fetus, and for the mother. Prolactin-secreting pituitary adenoma disrupts the functioning of the hypothalamic-pituitary-ovarian system. Patients have hypogonadotropic hypogonadism, oligomenorrhea, amenorrhea, galactorrhea, decreased libido, polycystic ovary syndrome, infertility. Key words: hyperprolactinemia, hyperparathyroidism, menstrual irregularities, infertility. For citation: Petrov Yu.A., Kupina A.D. Complications of the gestational period in patients with type 1 multiple endocrine neoplasia syndrome. Consilium Medicum. 2020; 22 (6): 15-18. DOI: 10.26442/20751753.2020.6.200140

About the authors

Yuri A. Petrov

Rostov State Medical University

Email: mr.doktorpetrov@mail.ru
д-р мед. наук, проф., зав. каф. акушерства и гинекологии Rostov-on-Don, Russia

Anastasia D. Kupina

Rostov State Medical University

соискатель каф. акушерства и гинекологии Rostov-on-Don, Russia

References

  1. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier Publ 2014; 1311-13.
  2. Agarwal SK. Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies. Int J Endocr Oncol 2014; 1: 153-61. doi: 10.2217/ije.14.16
  3. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol 2014; 386: 2-15. doi: 10.1016/j.mce.2013.08.002
  4. Khatamil F, Tavangar SM. Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives. Biomark Insights 2018; 13: 1177271918785129. doi: 10.1177/1177271918785129.
  5. Lodewijk LBP Kist JW, Conemans EB et al. Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1. Eur J Endocrinol 2015; 172: 337-42. doi: 10.1530/EJE-14-0897.
  6. Jeong YJ, Oh HK, Bong JG. Multiple endocrine neoplasia type 1 associated with breast cancer: a case report and review of the literature. Oncol Lett 2014; 8: 230-234. doi: 10.3892/ol.2014.2144.
  7. Демидова Т.Ю., Кишкович Ю.С. Синдром множественных эндокринных неоплазий 1-го типа. Consilium Medicum. 2018; 20 (4): 59-62. doi: 10.26442/2075-1753_2018.4.59-62
  8. Khatami F, Tavangar SM. Current diagnostic status of pheochromocytoma and future perspective: a mini review. Iran J Pathol 2017; 12: 313-22.
  9. Valdes N, Navarro E, Mesa J et al. RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation. Eur J Endocrinol 2015; 172: 301-7. doi: 10.1530/EJE-14-0818
  10. Купина А.Д., Петров Ю.А., Березовская К.Е. Особенности патогенеза и диагностики феохромоцитомы и параганглиомы во время беременности. Современные проблемы науки и образования. 2019; (3). www.science-education.ru/ru/article/view?id=28778.
  11. Wells SA, Jr, Asa SL, Dralle H et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid 2015; 25: 567-610. doi: 10.1089/thy.2014.0335
  12. Эндокринология. Национальное руководство. Под ред. И.И. Дедова. М.: ГЭОТАР-Медиа, 2016.
  13. Norton JA, Krampitz G, Jensen RT Multiple Endocrine Neoplasia: Genetics & Clinical Management. Surgl Oncol Clin N Am 2015; 24 (4): 795-832. doi: 10.1016/j.soc.2015.06.008
  14. Bartsch DK, Albers M, Knoop R et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab 2014; 99: E2387-2391. doi: 10.1210/jc.2013-4432
  15. Древаль АВ. Эндокринология: руководство для врачей. М.: ГЭОТАР-Медиа, 2016.
  16. Chung YJ, Hwang S, Jeong JJ et al. Genetic and epigenetic analysis in Korean patients with multiple endocrine neoplasia type 1. Endocrinol Metab 2014; 29: 270-9. doi: 10.3803/EnM.2014.29.3.270
  17. Di Meo G, Sgaramella LI, Ferraro V et al. Parathyroid carcinoma in multiple endocrine neoplasm type 1 syndrome: case report and systematic literature review. Clin Exp Med 2018; 18: 585-93. doi: 10.1007/s10238-018-0512-7
  18. Goudet P, Le Bras A, Cardot-Bauters C et al. MEN1 disease occurring before 21 years old. A 160-patient cohort study from the GTE (Groupe d’etude des Tumeurs Endocrines). J Clin Endocrinol Metab 2015; 100 (4): 1568-77. doi: 10.1210/jc.2014-3659
  19. Schnatz PF, Curry SL. Primary hyperparathyroidism in pregnancy: evidence-based management. Obstet Gynecol Surv 2002; 57 (6): 365-76.
  20. Мокрышева Н.Г., Мамедова E.O., Пигарова Е.А. и др. Синдром множественных эндокринных неоплазий 1-го типа с тремя классическими компонентами и глиомой хиазмы: особенности поражения органов-мишеней (обзор литературы и клиническое наблюдение). Терапевтический архив. 2015; 87 (12): 122-7.
  21. Mistry M, Gupta M, Kaler M. Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications. Obstet Med 2014; 7 (3): 123-5. doi: 10.1177/1753495X14532634
  22. Singh Ospina NTG, Lee RA, Reading CC et al. Safety and efficacy of percutaneous parathyroid ethanol ablation in patients with recurrent primary hyperparathyroidism and multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2015; 100: E87-90. doi: 10.1210/jc.2014-3255
  23. Montenegro FLM, Brescia MDG, Lourenco DM Jr et al. Could the less-than subtotal parathyroidectomy be an option for treating young patients with multiple endocrine neoplasia type 1-related hyperparathyroidism? Front Endocrinol 2019; 10: 123. doi: 10.3389/fendo.2019.00123
  24. Hultin H, Hellman P, Lundgren E et al. Association of parathyroid adenoma and pregnancy with preeclampsia. J Clin Endocrinol Metab 2009; 94 (9): 3394-9. doi: 10.1210/jc.2009-0012
  25. Калинин А.П., Котова И.В., Бритвин Т.А. и др. Гиперкальциемический криз. Альманах клинической медицины.2014;32:101-4.
  26. Tonelli F, Marini F, Giusti F, Brandi ML. Total and subtotal parathyroidectomy in young patients with multiple endocrine neoplasia type 1-related primary hyperparathyroidism: potential post-surgical benefits and complications. Front Endocrinol 2018; 9: 558. doi: 10.3389/fendo.2018.00558
  27. Lairmore TCGC, Quinn CE, Sigmond BR et al. A randomized, prospective trial of operative treatments for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 2014; 156 (6): 1326-34. doi: 10.1016/j.surg.2014.08.006
  28. Daglar HK, Kirbas A, Biberoglu E et al. Management of a multiple endocrine neoplasia type 1 during pregnancy: A case report and review of the literature. J Exp Ther Oncol 2016; 11 (3): 217-20.
  29. Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г. и др. Первичный гиперпаратиреоз: клиника, диагностика, дифференциальная диагностика, методы лечения. Клинические рекомендации. Проблемы эндокринологии. 2016; 60 (6): 40-77.
  30. De Laat JM, van Leeuwaarde RS, Valk GD. The importance of an early and accurate MEN1 diagnosis. Front Endocrinol 2018; 9: 533. doi: 10.3389/fendo.2018.00533
  31. Kamilaris C, Stratakis CA. Multiple Endocrine Neoplasia Type 1 (MEN1): An Update and the Significance of Early Genetic and Clinical Diagnosis. Front Endocrinol 2019; 10: 1-15. doi: 10.3389/fendo.2019.00339
  32. Мокрышева Н.Г., Липатенкова А.К., Таллер Н.А. Первичный гиперпаратиреоз и беременность. Акушерство и гинекология. 2016; 10: 18-25. doi: 10.18565/aig.2016.10.18-25
  33. Nunes VSSG, Perone D, Conde SJ, Nogueira CR. Frequency of multiple endocrine neoplasia type 1 in a group of patients with pituitary adenoma: genetic study and familial screening. Pituitary 2014; 17: 30-37. doi: 10.1007/s11102-013-0531-z
  34. Мамедова Е.О., Мокрышева Н.Г., Пигарова Е.А. и др. Фенокопии синдрома множественных эндокринных неоплазий 1 типа: роль генов, ассоциированных с развитием аденом гипофиза. Проблемы эндокринологии. 2016; (4): 4-10.
  35. Majumdar A, Mangal NS. Hyperprolactinemia. J Human Reprod Sci 2013; 6 (3): 168-75. doi: 10.4103/0974-1208.121400
  36. Петров Ю.А. Здоровье семьи - здоровье нации. М.: Медицинская книга, 2018.
  37. Тевосян Л.Х., Древаль А.В., Крюкова И.В., Барсуков И.А. Синдром множественной эндокринной неоплазии 1-го типа: клинический случай. РМЖ. 2017; 1: 61-3.
  38. Ветров В.В., Васильев В.Е., Иванов Д.О. и др. Синдром гиперстимуляции яичников (клиническое наблюдение). Детская медицина Северо-Запада. 2012; 3 (2): 61-5.
  39. Петров Ю.А., Купина А.Д., Шаталов А.Е. Роль пролактиномы в развитии репродуктивных нарушений. Современные проблемы науки и образования. 2019; 5. http://science-education.ru/ru/ article/view?id=29200

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies